ModernaMRNA
About: Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Employees: 5,600
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
14% more funds holding in top 10
Funds holding in top 10: 7 [Q3] → 8 (+1) [Q4]
4.01% more ownership
Funds ownership: 67.61% [Q3] → 71.62% (+4.01%) [Q4]
10% less funds holding
Funds holding: 770 [Q3] → 693 (-77) [Q4]
10% less repeat investments, than reductions
Existing positions increased: 218 | Existing positions reduced: 243
20% less call options, than puts
Call options by funds: $927M | Put options by funds: $1.15B
21% less first-time investments, than exits
New positions opened: 129 | Existing positions closed: 164
34% less capital invested
Capital invested by funds: $17.3B [Q3] → $11.5B (-$5.88B) [Q4]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
8 analyst ratings
UBS Eliana Merle 35% 1-year accuracy 8 / 23 met price target | 120%upside $78 | Buy Maintained | 19 Feb 2025 |
RBC Capital Luca Issi 21% 1-year accuracy 12 / 56 met price target | 13%upside $40 | Sector Perform Reiterated | 18 Feb 2025 |
Barclays Gena Wang 17% 1-year accuracy 5 / 29 met price target | 27%upside $45 | Equal-Weight Downgraded | 18 Feb 2025 |
B of A Securities Tim Anderson 56% 1-year accuracy 5 / 9 met price target | 4%downside $34 | Underperform Maintained | 11 Feb 2025 |
Goldman Sachs Salveen Richter 27% 1-year accuracy 4 / 15 met price target | 44%upside $51 | Neutral Downgraded | 29 Jan 2025 |
Financial journalist opinion
Based on 54 articles about MRNA published over the past 30 days
